206 related articles for article (PubMed ID: 32096153)
1. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
[TBL] [Abstract][Full Text] [Related]
2. LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer.
Cui TJ; Lin GS; Dai YM; Zheng JP; Chen Z; Chen Q; Zheng Y; Lin X
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):264-273. PubMed ID: 31389597
[TBL] [Abstract][Full Text] [Related]
3. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
4. LncRNA HANR aggravates the progression of non-small cell lung cancer via mediating miRNA-140-5p.
Li SJ; Wu YX; Liang YH; Gao Y; Wu AB; Zheng HY; Yang ZX
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):704-711. PubMed ID: 32016972
[TBL] [Abstract][Full Text] [Related]
5. USP3 promotes proliferation of non-small cell lung cancer through regulating RBM4.
Liao XH; Wang Y; Zhong B; Zhu SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3143-3151. PubMed ID: 32271432
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA CRNDE promotes non-small cell lung cancer progression via sponging microRNA-338-3p.
Jing H; Xia H; Qian M; Lv X
Biomed Pharmacother; 2019 Feb; 110():825-833. PubMed ID: 30554121
[TBL] [Abstract][Full Text] [Related]
7. MiR-1471 protects the aggravation of non-small-cell lung carcinoma by targeting FOXL1.
Shi D; Zhang K; Li G; Zhao Y
Biofactors; 2020 Sep; 46(5):734-742. PubMed ID: 33045131
[TBL] [Abstract][Full Text] [Related]
8. Translation regulatory long non-coding RNA 1 negatively regulates cell radiosensitivity via the miR-22-3p/SP1 axis in non-small cell lung cancer.
Zhong M; Fang Z; Guo W; Yu X
Clin Respir J; 2024 Jan; 18(1):e13734. PubMed ID: 38286742
[TBL] [Abstract][Full Text] [Related]
9. LncRNA WT-AS inhibits metastatic ability of non-small cell lung cancer by regulating KLK13.
Wang Y; Tan TZ; Wang LQ; Zhang K
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9429-9437. PubMed ID: 33015785
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-424-5p inhibits the development of non-small cell LCa by binding to ITGB1.
Xu ZL; Zhang M; Chen SX; Qiu M; Zhang Q; Gao LP; Li JDX
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8921-8930. PubMed ID: 31696479
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-597 inhibits NSCLC progression through negatively regulating CDK2 expression.
Yu DJ; Li YH; Zhong M
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4288-4297. PubMed ID: 32373965
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA OR3A4 is associated with poor prognosis of human non-small cell lung cancer and regulates cell proliferation via up-regulating SOX4.
Zhong M; Wang WL; Yu DJ
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6524-6530. PubMed ID: 31378892
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of lncRNA FEZF1-AS1 in promoting the occurrence and development of oral squamous cell carcinoma through targeting miR-196a.
Xu L; Hou TJ; Yang P
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6505-6515. PubMed ID: 31378890
[TBL] [Abstract][Full Text] [Related]
14. LncRNA FBXL19-AS1 promotes proliferation and metastasis via regulating epithelial-mesenchymal transition in non-small cell lung cancer.
Yu DJ; Li YH; Zhong M
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4800-4806. PubMed ID: 31210311
[TBL] [Abstract][Full Text] [Related]
15. LncRNA ASB16-AS1 promotes proliferation and inhibits apoptosis of non small cell lung cancer cells by activating the Wnt/β catenin signaling pathway.
Tan LJ; Liu JT; Yang M; Ju T; Zhang YS
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1870-1876. PubMed ID: 32141556
[TBL] [Abstract][Full Text] [Related]
16. LncRNA WTAPP1 promotes proliferation of laryngeal carcinoma cells through regulating microRNA-592.
Shi XY; Lin JJ; Ge XJ; Shi Y
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9532-9540. PubMed ID: 33015795
[TBL] [Abstract][Full Text] [Related]
17. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis.
Hao XZ; Yang K
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7399-7407. PubMed ID: 31539127
[TBL] [Abstract][Full Text] [Related]
18. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
Chen ZY; Liu HY; Jiang N; Yuan JM
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
[TBL] [Abstract][Full Text] [Related]
19. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
20. LncRNA BX357664 inhibits the proliferation and invasion of non-small cell lung cancer cells.
Yang J; Du YM; Li B
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):660-669. PubMed ID: 30720174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
